Electronic Clinical Challenges and Images in GIAn Unusual Case of Esophagitis
Section snippets
Answer to: Image 2: Gastroesophageal Reflux Disease
Dabigatran is a novel, direct thrombin inhibitor (factor IIa) that is noninferior to warfarin in protecting patients from nonvalvular atrial fibrillation and in treating or preventing thromboembolic events.1 Gastroesophageal reflux disease is reportedly the most predominant nonbleeding adverse events in patients taking this medication.2 Although generally well-tolerated, as demonstrated in this case, a pill-induced esophagitis mediated by dabigatran can occur and is suggested to happen in as
References (3)
- et al.
Dabigatran versus warfarin in patients with atrial fibrillation
N Engl J Med
(2009)
Cited by (3)
Drugs that affect blood coagulation, fibrinolysis and hemostasis
2021, Side Effects of Drugs AnnualCitation Excerpt :Computed tomography scanning revealed diffuse circumferential esophageal thickening and endoscopy showed a large, longitudinal area of mucosal sloughing in the middle-third of the esophagus. The authors attributed her diagnosis to dabigatran (Argueta et al., 2020) [A]. A case report described a case of chronic progressive immune hemolytic anemia attributed to dabigatran.
From Tartaric Acid to Grapes—An Unusual Form of Esophagitis
2023, Journal fur Gastroenterologische und Hepatologische ErkrankungenAnalysis of the clinical characteristics of dabigatran-induced oesophagitis
2023, European Journal of Hospital Pharmacy
Conflicts of interest The authors disclose no conflicts.